Researchers Developed Automated Genetic Screening Platform
A new in silico tool accelerates cellular reprogramming research by automating complex multi-gene perturbation screens.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Do you support prioritizing AI-driven virtual genetic screening to reduce reliance on laboratory animal testing?
Researchers have developed the ISP Platform, an automated system that utilizes Geneformer to conduct in silico perturbation screens. This technology enables scientists to identify optimal gene overexpression sequences required for cellular state transitions.
Why it matters
The platform provides a structured framework to guide essential experimental validation while potentially reducing the need for exploratory animal use in biotech research. By automating sequential screens, it streamlines the identification of complex genetic modulators.
The ISP Platform automates complex, sequential multi-gene perturbation screens using Geneformer models. The system successfully identified an optimal overexpression sequence for pluripotency among 24 different factor permutations.
The players
Geneformer
Geneformer is an artificial intelligence foundation model designed to analyze and predict genetic expression patterns and cellular behaviors.
ISP Platform
The ISP Platform is an automated in silico tool developed to perform sequential genetic perturbation screens for cellular research.
The details
The platform automates perturbation screens by chaining each analysis step from the preceding cell state, facilitating both human and mouse model comparisons. This cross-species capability allows researchers to apply mouse models to human cells, revealing key translation-related biological terms.
Timeline
September 24, 2026: The study detailing the new platform was published.
The Tech Race
The ISP Platform extends the analytical capabilities of the Geneformer foundation model. This integration represents a shift toward automating discovery in synthetic biology, replacing manual, trial-and-error laboratory methods with scalable digital workflows.
This automation tool accelerates the research timeline for developing induced pluripotent stem cells, potentially speeding up the path toward new regenerative medicine therapies. It allows researchers to optimize genetic interventions digitally before moving to expensive and time-consuming physical experiments.
The takeaway
By digitizing complex cellular transition screens, this platform marks a significant transition from manual experimentation to AI-driven biological design. Researchers can adopt these digital frameworks to prioritize high-probability experiments and minimize wasted laboratory resources.
Further reading
Learn more about the latest innovations in Biotech.
More information
Access the complete findings in the scientific study paper published on the platform host.
Source note: This article includes information reported by Biorxiv.
Live Poll
Do you support prioritizing AI-driven virtual genetic screening to reduce reliance on laboratory animal testing?
